Clinical and serological resolution of pembrolizumab associated Sjögren's syndrome: long-term follow-up

Rheumatology (Oxford). 2021 Dec 24;61(1):e22-e24. doi: 10.1093/rheumatology/keab698.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects*
  • Male
  • Sjogren's Syndrome / chemically induced*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immune Checkpoint Inhibitors
  • pembrolizumab